Serbia Pharmaceuticals and Healthcare Report Q3 2014, New Report Launched

The new Serbian government is actively trying to stabilise the country's fiscal position through cutting spending, encouraging outside investment and demand pickup for Serbian exports in order to reduce its debt burden. However, pharmaceutical spending is also a target for cuts. Local drug makers are set to feel the worst of these new measures as they cannot compete on cost compared to larger players in the market. The Serbian government has amended the Medicines Act with the specific aim of considerably lowering drug prices, and therefore reducing the liabilities of the National Health Insurance Fund (RFZO). Serbia's pharmaceutical spending growth will remain depressed for the next two to three years. Overall, Serbia's pharmaceutical market's high price-sensitivity will constrain the market's short-term potential, although we are optimistic towards the market's long-term growth prospects.

Headline Expenditure Projections

• Pharmaceuticals: RSD90.46bn (USD1.05bn) in 2013 to RSD97.00bn (USD1.06bn) in 2014; +7.2% in local currency terms and +1.2% in US dollar terms.
• Healthcare: RSD389.82bn (USD4.53bn) in 2013 to RSD412.61bn (USD4.53bn) in 2014; +5.8% in local currency terms and -0.1% in US dollar terms.

Spanning over 132 pages, “Serbia Pharmaceuticals and Healthcare Report Q3 2014” report covering the Industry Forecast, Market Overview, Company Profile and Methodology.

See Table of contents & Purchase this publication at: -   http://mrr.cm/ZmW